We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$337M
Cap. Flow %
-21.88%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 10.49%
2 Financials 0.07%
3 Technology 0.07%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOLX
76
CALL
DELISTED
Hologic
HOLX
$2.29M 0.15%
+1,110
New +$23.6K
ACAD icon
77
PUT
Acadia Pharmaceuticals
ACAD
$4.45B
$2.29M 0.15%
+833
New +$17.4K
INSM icon
78
PUT
Insmed
INSM
$22.6B
$2.25M 0.15%
+1,440
New +$18.3K
PCYC
79
PUT
DELISTED
PHARMACYCLICS INC
PCYC
$2.15M 0.14%
+155
New +$17.2K
SZYM
80
DELISTED
SOLAZYME INC COM STK (DE)
SZYM
$2.14M 0.14%
+198,350
New +$2.26M
SZYM
81
PUT
DELISTED
SOLAZYME INC COM STK (DE)
SZYM
$2.12M 0.14%
1,964
+421
+27% +$4.79K
CASI
82
DELISTED
CASI Pharmaceuticals
CASI
$2.06M 0.13%
117,896
+637
+0.5% +$12.1K
LLY icon
83
PUT
Eli Lilly
LLY
$1.09T
$2.05M 0.13%
407
– –
XOMA
84
DELISTED
Xoma
XOMA
$2.04M 0.13%
+22,784
New +$2.07M
MDCO
85
CALL
DELISTED
Medicines Co
MDCO
$2.03M 0.13%
+605
New +$19.3K
VNDA icon
86
CALL
Vanda Pharmaceuticals
VNDA
$310M
$2M 0.13%
+1,827
New +$19.5K
AMRN
87
PUT
Amarin Corp
AMRN
$293M
$1.95M 0.13%
154
-184
-54% -$22K
MDGL icon
88
PUT
Madrigal Pharmaceuticals
MDGL
$12.4B
$1.89M 0.12%
85
+23
+37% +$4.89K
RXII
89
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$1.81M 0.12%
7,990
+6,699
+519% +$1.52M
UNXL
90
PUT
DELISTED
Uni-Pixel, Inc.
UNXL
$1.77M 0.12%
998
+406
+69% +$6.47K
ELN
91
CALL
DELISTED
ELAN CORP ADS(RP1 ORD4IRISH PN
ELN
$1.71M 0.11%
1,100
-7,229
-87% -$109K
CEMP
92
DELISTED
Cempra, Inc.
CEMP
$1.71M 0.11%
148,572
-1,428
-1% -$12.5K
PCYC
93
DELISTED
PHARMACYCLICS INC
PCYC
$1.71M 0.11%
+12,350
New +$1.37M
LLY icon
94
Eli Lilly
LLY
$1.09T
$1.67M 0.11%
33,156
+14,934
+82% +$782K
VNDA icon
95
PUT
Vanda Pharmaceuticals
VNDA
$310M
$1.66M 0.11%
+1,515
New +$16.2K
INCY icon
96
CALL
Incyte
INCY
$26B
$1.64M 0.11%
431
– –
TPST icon
97
Tempest Therapeutics
TPST
$13.9M
$1.6M 0.1%
+55
New +$1.95M
ARIA
98
CALL
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.6M 0.1%
870
+576
+196% +$11.2K
SVRA icon
99
Savara
SVRA
$1.09B
$1.6M 0.1%
51,994
-58,176
-53% -$1.81M
TLPH icon
100
Talphera
TLPH
$67.5M
$1.59M 0.1%
+7,404
New +$1.62M
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management withdrew a net $337M in Q3 2013, closing 65 positions and reducing 41 holdings. Its most notable exit was AbbVie, an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 11% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Tompkins Financial worth $1.02M.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.